{"product_id":"hd-labs-retatrutide-32-vial","title":"HD Labs Retatrutide 32 Vial","description":"\u003cul\u003e\n\u003cli\u003eRetatrutide is an unregistered triple-agonist peptide (GLP-1\/GIP\/glucagon) sold in South Africa as a 32mg lyophilised vial requiring reconstitution with bacteriostatic water.\u003c\/li\u003e\n\u003cli\u003eThe 2023 NEJM Phase 2 trial reported 24.2% mean weight loss at 48 weeks on the 12mg weekly dose—the highest published figure for any obesity peptide to date.\u003c\/li\u003e\n\u003cli\u003eTitration follows a four-week stepwise protocol: 2mg weeks 1–4, 4mg weeks 5–8, 6mg weeks 9–12, with optional escalation to 12mg under prescriber supervision.\u003c\/li\u003e\n\u003cli\u003eVial format costs 15–25% less per milligram than the pre-filled pen but requires sterile reconstitution technique.\u003c\/li\u003e\n\u003cli\u003eRetatrutide is not SAHPRA-registered and is accessible only via Section 21 prescriber routes in South Africa.\u003c\/li\u003e\n\u003cli\u003eGI side effects (nausea, vomiting, diarrhoea) peak during dose escalation and typically settle within 1–2 weeks at a stable dose.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 id=\"what-is-hd-labs-retatrutide-32mg-\"\u003eWhat Is HD Labs Retatrutide 32mg?\u003c\/h2\u003e\n\u003cp\u003eHD Labs Retatrutide 32mg is a South African-compounded vial of retatrutide (Eli Lilly and Company investigational code\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eLY3437943\u003c\/strong\u003e), a single peptide molecule that simultaneously activates three metabolic receptors: GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-dependent Insulinotropic Polypeptide), and glucagon [13]. HD Labs sells it in 32mg lyophilised vials for reconstitution, and it is\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003enot\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eregistered with SAHPRA or approved by the FDA (Food and Drug Administration) or EMA (European Medicines Agency) as of early 2026 [1][9][11].\u003c\/p\u003e\n\u003cp\u003eThe triple-agonist mechanism separates it from earlier injectables because each receptor pathway controls a distinct metabolic lever:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eGLP-1 receptor agonist activity\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003e— slows gastric emptying and suppresses appetite, the same axis semaglutide acts on to reduce caloric intake.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGIP receptor agonist activity\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003e— improves insulin sensitivity and reduces insulin resistance, the second axis tirzepatide adds to enhance glucose handling and reduce hepatic fat.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlucagon receptor agonist activity\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003e— increases resting energy expenditure via thermogenesis, a third lever neither semaglutide nor tirzepatide pulls, which raises baseline calorie burn independent of appetite suppression.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat third receptor is why the 2023 NEJM Phase 2 trial (Jastreboff et al.) recorded a mean 24.2% body weight reduction at 48 weeks on the 12mg weekly dose, the highest figure published for any obesity peptide to date [13].\u003c\/p\u003e\n\u003ch2 id=\"triple-agonist-vs-dual-vs-single-clinical-outcomes-compared\"\u003eTriple Agonist vs Dual vs Single: Clinical Outcomes Compared\u003c\/h2\u003e\n\u003cp\u003eRetatrutide produced the largest mean weight loss of the three leading obesity peptides in Phase 2 trials, but no head-to-head RCT (Randomized Controlled Trial) exists as of 2026, so the figures below come from separate trials with different durations and populations.\u003c\/p\u003e\n\u003cp\u003eGlucagon receptor agonism raises resting energy expenditure by stimulating hepatic glucose output and mitochondrial activity — a thermogenesis effect that semaglutide does not produce because it lacks glucagon signalling. Tirzepatide’s GIP arm improves insulin sensitivity and adipocyte lipid handling, but neither GLP-1 nor GIP directly increases calorie burn at rest. Adding glucagon agonism is the mechanistic reason retatrutide’s Phase 2 curve was still trending downward at week 48 without a clear plateau [3], suggesting continued weight loss beyond the trial endpoint.\u003c\/p\u003e\n\u003ch3 id=\"why-these-numbers-are-not-a-clean-comparison\"\u003eWhy these numbers are not a clean comparison\u003c\/h3\u003e\n\u003cp\u003eThe 24.2% vs 22.5% vs 14.9% framing is cross-trial, and the durations diverge meaningfully. Retatrutide’s 48-week figure was measured 20 to 24 weeks earlier in the treatment arc than the SURMOUNT-1 and STEP 1 endpoints. Weight-loss curves for incretin therapies typically continue downward past week 48. A fair retatrutide-vs-tirzepatide comparison at matched 72-week timepoints does not exist in the published literature as of early 2026 because the Phase 2 trial stopped at 48 weeks, and TRIUMPH Phase 3 readouts are still pending [4][5].\u003c\/p\u003e\n\u003cp\u003eBaseline populations also differ: STEP 1 enrolled BMI ≥30 (or ≥27 with comorbidity) non-diabetics, SURMOUNT-1 used similar criteria, and the 2023 Jastreboff retatrutide trial enrolled adults with BMI ≥30 or ≥27 with weight-related comorbidity. Subgroup sizes, ethnic composition, and run-in protocols all vary, so the trial cohorts are not directly comparable.\u003c\/p\u003e\n\u003ch2 id=\"retatrutide-dosage-instructions-full-titration-schedule\"\u003eRetatrutide Dosage Instructions: Full Titration Schedule\u003c\/h2\u003e\n\u003cp\u003eThe HD Labs Retatrutide 32mg titration schedule mirrors the 2023 NEJM Phase 2 protocol: start at 2mg subcutaneously once weekly for four weeks, escalate to 4mg weekly for weeks 5–8, then move to 6mg weekly from week 9 onward if tolerance allows [12]. Retatrutide’s 5–7 day half-life supports once-weekly dosing because steady-state plasma concentrations remain stable across the injection interval.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWeeks 1–4:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003e2mg subcutaneous injection once weekly. Most GI side effects (nausea, mild reflux, transient appetite suppression overshoot) emerge in this window because the GLP-1 and GIP receptors are newly activated.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWeeks 5–8:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003e4mg SC once weekly if week 4 was tolerated without persistent vomiting or volume depletion. Hold the dose another two weeks if side effects are still active — receptor downregulation takes time.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWeeks 9–12:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003e6mg SC once weekly based on weight-loss response and tolerability. Some users hold at 4mg if appetite suppression is already adequate and further escalation risks unmanageable nausea.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWeek 13+:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eContinue at the lowest effective dose. Jastreboff et al. (2023) used up to 12mg weekly in the Phase 2 trial, but escalation beyond 6mg should only happen under prescriber supervision [12] because real-world safety data at higher doses remain limited.\u003c\/p\u003e\n\u003ch3 id=\"why-slow-titration-matters\"\u003eWhy slow titration matters\u003c\/h3\u003e\n\u003cp\u003eStepwise dose increases allow GLP-1, GIP, and glucagon receptors to downregulate progressively. This is why gradual escalation cuts nausea and vomiting rates compared with starting at therapeutic doses. The 2023 Phase 2 trial used four-week dose steps for this reason [12]. Clinic-reported data show that jumping from 2mg straight to 8mg is the single most common cause of treatment dropout in incretin peptide therapy [1].\u003c\/p\u003e\n\u003ch3 id=\"injection-site-rotation\"\u003eInjection site rotation\u003c\/h3\u003e\n\u003cp\u003eInject subcutaneously into the abdomen (avoiding a 5cm radius around the navel), outer thigh, or back of the upper arm. Rotate sites each week to prevent lipohypertrophy and erratic absorption — repeated injections in the same spot can create scar tissue that alters drug uptake. A 32mg vial yields roughly 16 weeks at 2mg, 8 weeks at 4mg, or 5 weeks at 6mg weekly, before accounting for reconstitution losses.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Delinquent","offers":[{"title":"Default Title","offer_id":46933179367561,"sku":null,"price":2030.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0743\/0438\/9257\/files\/hdlabsreta32vial.png?v=1781530581","url":"https:\/\/www.delinquent.co.za\/products\/hd-labs-retatrutide-32-vial","provider":"Delinquent","version":"1.0","type":"link"}